Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Indolent Non-Hodgkin's Lymphoma × obinutuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88 Lymphoma, Follicular 50 Lymphoma, Non-Hodgkin 36 Lymphoma, Large B-Cell, Diffuse 29 Lymphoma 29 Lymphoma, Mantle-Cell 26 Lymphoma, B-Cell, Marginal Zone 22 Lymphoma, B-Cell 18 Recurrence 13 Neoplasms 11 Leukemia 7 Leukemia, B-Cell 5 Burkitt Lymphoma 5 Leukemia, Hairy Cell 4 Waldenstrom Macroglobulinemia 3 Neoplasm, Residual 3 Melanoma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Disease 2 Dendritic Cell Sarcoma, Interdigitating 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bronchiolitis Obliterans Syndrome 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Tumor Lysis Syndrome 1 Solid Cancers 1

Interventions

obinutuzumab 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01889797 2017-05-05

PrE0401

PrECOG, LLC.

Phase 2 Terminated

32 enrolled 14 charts

Indolent Non-Hodgkin's Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡